Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review.
COVID-19
Cytokine storm
Mavrilimumab
Monoclonal antibody
SARS-CoV2
Journal
Infection & chemotherapy
ISSN: 2093-2340
Titre abrégé: Infect Chemother
Pays: Korea (South)
ID NLM: 101531537
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
15
09
2020
accepted:
17
02
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
ppublish
Résumé
Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening complications. Mavrilimumab is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. During an inflammation, Granulocyte-macrophage colony-stimulating factor (GM-CSF) release is crucial to driving both innate and adaptive immune responses. The GM-CSF immune response is triggered when an antigen attaches to the host cell and induces the signaling pathway. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.
Identifiants
pubmed: 34409778
pii: 53.1
doi: 10.3947/ic.2020.0109
pmc: PMC8032909
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1-12Informations de copyright
Copyright © 2021 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS.
Déclaration de conflit d'intérêts
No conflicts of interest.
Références
Biochem Biophys Res Commun. 2020 Sep 10;530(1):10-14
pubmed: 32828269
Int J Toxicol. 2015 Jul-Aug;34(4):355-65
pubmed: 26015504
Arthritis Rheumatol. 2018 Jan;70(1):49-59
pubmed: 28941039
Immunol Rev. 2012 Nov;250(1):277-302
pubmed: 23046136
Ann Rheum Dis. 2011 Sep;70(9):1542-9
pubmed: 21613310
Int J Cell Cloning. 1990 Jan;8 Suppl 1:35-44; discussion 44-5
pubmed: 2157777
Expert Opin Investig Drugs. 2019 Jul;28(7):573-581
pubmed: 31208237
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Core Evid. 2014 Mar 12;9:41-8
pubmed: 24648832
JAMA Intern Med. 2021 Jan 1;181(1):71-78
pubmed: 32910179
J Interferon Cytokine Res. 2015 Aug;35(8):585-99
pubmed: 25803788
Mod Rheumatol. 2015 Jan;25(1):21-30
pubmed: 24720551
Trends Immunol. 2002 Aug;23(8):403-8
pubmed: 12133803
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Arthritis Rheumatol. 2018 May;70(5):679-689
pubmed: 29361199
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Expert Rev Clin Immunol. 2015 Apr;11(4):457-65
pubmed: 25748625
Blood. 2003 Feb 15;101(4):1308-15
pubmed: 12393492
Nat Rev Immunol. 2020 Aug;20(8):507-514
pubmed: 32576980
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Lancet Rheumatol. 2020 Aug;2(8):e465-e473
pubmed: 32835256
Lancet. 2003 May 24;361(9371):1773-8
pubmed: 12781536
Front Immunol. 2020 Jul 03;11:1625
pubmed: 32719685
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Biochem Pharmacol. 2020 Oct;180:114169
pubmed: 32710969
Curr Opin Immunol. 2009 Oct;21(5):514-21
pubmed: 19796925
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Front Immunol. 2020 May 29;11:1131
pubmed: 32574265